FDA 483 - Novo Nordisk A/S - March 25, 2024

An FDA inspection of Novo Nordisk A/S in Kalundborg Sjalland identified significant deficiencies in their drug substance manufacturing processes. Observations included inadequate water system sampling and control, incomplete manufacturing records and process descriptions, and insufficient validation documentation. These issues collectively indicate a lack of robust quality assurance and control over their drug substance production.